Loading clinical trials...
Loading clinical trials...
A Pilot Study of Molecularly Tailored Therapy for Patients With Metastatic Pancreatic Cancer
Patient therapy is tailored according to the molecular profile of the patient's tumor.
This study is for patients with metastatic pancreatic cancer (cancer that has spread to other parts of the body). The purpose of this study is to determine whether molecularly tailored therapy can improve the effectiveness of standard chemotherapy combinations for patients with metastatic pancreatic cancer. A series of special tests will be performed on a sample of tumor, and based on the results subjects will be assigned to one of seven chemotherapy treatments, with each being the combination of two standard chemotherapies. Each of these combinations has been safely used in patients with pancreatic or other types of cancer. The purpose of this study is to to determine the ability to personalize therapy in this manner, and to determine how many patients a larger study would need. A second purpose is not to determine if one doublet is better than another. Rather, this second purpose is to show that for all patients enrolled in this protocol who have been assigned a doublet based on their tumor's molecular analysis (molecular tailoring), treatment response will be better than would be expected compared to patients who have been treated in the past with no molecular tailoring.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Georgetown University- Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, United States
MedStar Montgomery Medical Center
Olney, Maryland, United States
Start Date
December 1, 2012
Primary Completion Date
June 1, 2016
Completion Date
January 24, 2018
Last Updated
April 9, 2018
19
ACTUAL participants
Gem-OX
DRUG
Gem-5FU
DRUG
Gem-Tax
DRUG
Modified FOLFOX-6
DRUG
Ox-Tax
DRUG
FOLFIRI
DRUG
Tax-Iri
DRUG
Lead Sponsor
Georgetown University
NCT04550494
NCT05053971
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions